Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Comparative Study to Evaluate Efficacy of Anticancer Chemotherapy in Predicting Prognosis and Determining Chemotherapy Method in Early Hormone Receptor-positive Breast Cancer Patients With Clinicopathological High Risk and GenesWell™ BCT Low Risk at Multi-center in Korea

NCT04278469 is registered in ClinicalTrials.gov with Gencurix, Inc. as lead sponsor.

NCT NCT04278469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04278469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Comparative Study to Evaluate Efficacy of Anticancer Chemotherapy in Predicting Prognosis and Determining Chemotherapy Method in Early Hormone Receptor-positive Breast Cancer Patients With Clinicopathological High Risk and GenesWell™ BCT Low Risk at Multi-center in Korea
Lead sponsor
Gencurix, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
January 11, 2019
Completion date
January 31, 2029
Enrollment
194 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early hormone receptor-positive breast cancer